Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females.
about
Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPVThe combined influence of oral contraceptives and human papillomavirus virus on cutaneous squamous cell carcinomaExpanding the scope of nursing research in low resource and middle resource countries, regions, and states focused on cervical cancer prevention, early detection, and controlCervical screening within HIV care: findings from an HIV-positive cohort in UkraineHigh HIV, HPV, and STI prevalence among young Western Cape, South African women: EVRI HIV prevention preparedness trial.Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.Genital human papillomavirus infection among women in Bangladesh: findings from a population-based surveySpontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype.Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan.Human papillomavirus infection and risk factors in a cohort of Tuscan women aged 18-24: results at recruitmentCigarette smoking is an independent risk factor for cervical intraepithelial neoplasia in young women: a longitudinal studySeroprevalence of human papillomavirus immunoglobulin G antibodies among women presenting at the reproductive health clinic of a university teaching hospital in Nigeria.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerPredicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.Do clinical data and human papilloma virus genotype influence spontaneous regression in grade I cervical intraepithelial neoplasia?Modeling optimal cervical cancer prevention strategies in Nigeria.Reproductive factors associated to human papillomavirus infection in Iranian woman.Downregulation of Cdc2/CDK1 kinase activity induces the synthesis of noninfectious human papillomavirus type 31b virions in organotypic tissues exposed to benzo[a]pyrene.Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda.Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysisCondom and oral contraceptive use and risk of cervical intraepithelial neoplasia in Australian womenIncident cervical infections with high- and low-risk human papillomavirus (HPV) infections among mothers in the prospective Finnish Family HPV Study.Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.Management of low-grade cervical lesions in young women.Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa.Conservative management of adolescents with abnormal cytology and histology.The role of sexual behavior and human papillomavirus persistence in predicting repeated infections with new human papillomavirus types.Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load.Updated guidelines for papanicolaou tests, colposcopy, and human papillomavirus testing in adolescents.Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus.Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinantsGuidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theHuman papillomavirus concordance in heterosexual couples.Determinants of prevalent human papillomavirus in recently formed heterosexual partnerships: a dyadic-level analysisAssociation between human papillomavirus and human T-lymphotropic virus in indigenous women from the Peruvian Amazon.Prevalence and risk factors for cervical neoplasia: a cervical cancer screening program in Beijing.Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia.Incidence, clearance and predictors of human papillomavirus infection in women.Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.
P2860
Q26783973-243291D3-3D67-4CBF-83C2-8D5B3C846777Q28387851-B158C048-1C2E-457C-B343-242AD582606EQ28391812-F0303B61-1690-46F8-BF29-974BE435F0C5Q28730416-4E2BA818-C688-474D-AD2B-6C7C999CC059Q30206108-992A5E64-4579-46D8-AC02-313DF8ECE51AQ30573204-23DFC145-7B0D-426E-9CF4-929AC5128B55Q30856793-3F05DB45-5CB6-4E69-B0A2-16F5113F19E7Q33218333-74932287-B914-4050-9A06-60CF95C2E60DQ33523171-5C5FD769-2135-4F72-A7E9-C6B4B197588AQ33596805-ADFCDFAB-1F44-47B7-83B7-5042A1B3DD91Q33598568-F8FB05A8-A55B-42C7-997B-590BAA91FCE4Q33641116-56D1D537-9A5E-4F07-8AAA-17E8C2560964Q33650105-16438836-4179-4115-802B-C83A26003C44Q33708098-F3A57ECB-CAC7-4D29-944C-D7EBA4627265Q33724422-919DC00B-6363-4725-8D20-6D4259308782Q33743070-AB8963DD-BEFB-4D7A-9E5E-78BAA6DDA3EAQ33755002-437F80E9-ED27-41E0-B101-15C0CA3AA78BQ33783100-1FEFF040-7B6D-4541-BA4A-C7B0BC459692Q33826637-5ECB90E6-46A5-4DB3-8A13-C5ABF18308F6Q33863369-1D8DCFC0-C557-43F1-A544-311198394956Q33883532-8E9C18D0-F3FC-4F56-BEE8-B5721FF970CEQ33917313-7AA18218-1338-44AF-BBE7-B340460CC33EQ33940157-9D6910E4-2BC8-491D-A0DA-64ADDA7CDEC9Q33944133-DA742734-89FD-41B6-A58C-27B448E55507Q33998888-5415079B-B290-4EB9-A696-D596C44FD703Q34039900-8A615CF7-8F9A-40EB-B1D9-59BBDB081513Q34050415-29FC88E1-AF03-4C0E-838C-9BEC14DA89FAQ34059901-D4B02008-1D54-4C05-9CA7-CEC6892725ACQ34062235-40D8573B-FEDF-497D-9025-DBCABCC423F3Q34121746-893B92DE-824D-43C3-861A-FF057F4812D8Q34159707-84B0C4A9-CFDB-496B-BAA9-9A05E5F3052AQ34187446-16F772FB-51A4-4899-89CA-E284A17780E0Q34212799-4617E109-D37C-4732-89A6-2BEA5815EA4CQ34257094-C90053E1-F2D0-494B-809E-905394832AF9Q34315668-1F5FB07B-08E0-424C-AD3C-6700C5EA0EB5Q34406503-6B2621A1-1BF5-4B8F-9767-4772E790EBE2Q34448648-FA190472-DBD3-4352-A173-C1DC14639A0CQ34532192-AB15708D-0513-45BD-A675-CBCCA5CB3A4BQ34536772-131A46D7-A7FD-43BB-A834-CD4CA5690A72Q34549645-F86169CD-5E4D-455A-929A-AA284EFD42F8
P2860
Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Risks for incident human papil ...... development in young females.
@en
Risks for incident human papil ...... development in young females.
@nl
type
label
Risks for incident human papil ...... development in young females.
@en
Risks for incident human papil ...... development in young females.
@nl
prefLabel
Risks for incident human papil ...... development in young females.
@en
Risks for incident human papil ...... development in young females.
@nl
P2093
P356
P1476
Risks for incident human papil ...... development in young females.
@en
P2093
A B Moscicki
J Broering
J Palefsky
P304
P356
10.1001/JAMA.285.23.2995
P407
P577
2001-06-01T00:00:00Z